The Latest Cardiac and Vascular News
WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board […]
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure WARRINGTON, Pa., June 12, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: […]
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering of 3,686,006 shares of […]
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from The […]
US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High WARRINGTON, Pa., March 06, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the […]
Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions […]
WARRINGTON, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the Company’s Board of Directors has approved a […]
WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key […]
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders, today […]
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours The study also met several key […]
